Polyplus launches FectoVIR(R)-AAV GMP transfection reagent for large scale viral vector production to overcome commercial gene and cell therapy manufacturing barriers

Polyplus launches FectoVIR(R)-AAV GMP transfection reagent for large scale viral vector production to overcome commercial gene and cell therapy manufacturing barriers

Strasbourg, France, August 10, 2021 – Polyplus, a leading provider of upstream process solutions for advanced biologic and cell and gene therapy production from research to commercial-grade, today announces a new addition to the portfolio of proprietary transfection reagents for viral vector manufacturing. FectoVIR-AAV® GMP is a pharma-grade good manufacturing practice (GMP) reagent. This reagent has been specifically developed to enable large scale transfection applications, complementing the existing Polyplus FectoVIR®-AAV reagent line.

“In today’s market, transient transfection for adeno-associated virus (AAV) production is the predominant method for gene therapy development. However, manufacturers have struggled to find solutions that can produce the number of viral vectors needed to successfully scale promising therapies into late-stage clinical trials and commercialization,” said Mario Philips, CEO, Polyplus. “We have added FectoVIR-AAV GMP to the transfection reagent portfolio to help manufacturers alleviate major pain points with linear process scalability and flexibility. Users will be able to work from small scale process development stages to improve AAV production in suspension cell culture systems and more easily transition into large-scale GMP manufacturing activities.”

“Polyplus has added FectoVIR-AAV GMP as an essential addition to our comprehensive, high-performance transfection reagent portfolio designed to meet pharma-grade standards,” said Geraldine Guerin-Peyrou, Director of Marketing, Polyplus. “We have developed our product based on customer demand, building in flexibility down to the format of the reagents in either MPC connectors/weldable tubing or bottles to meet the needs of each process. And the performance of FectoVIR-AAV GMP remains market-leading with validation studies showing the ability to enhance AAV titers with a two- to three-fold increase in AAV productivity in suspension HEK-293 cell systems.”

Polyplus is continuing to grow its reagent portfolio and global footprint as it celebrates its 20th anniversary of the company. With the addition of FectoVIR-AAV GMP, Polyplus now offers the industry’s most complete range of transfection reagents for advanced therapy medicinal product (ATMP), viral and protein manufacturing from research to commercial scale. In addition, Polyplus’ global presence continues to advance with a state-of-the-art Vectura building coming online in France, the acquisition of Biowire and expansion in Shanghai in China, and plans for continued developments.

About Polyplus

Polyplus is a leading provider of upstream process solutions for advanced biologic and cell and gene therapy production from research to commercial grade. Leveraging more than 20 years of innovative nucleic acid transfection expertise, upstream solutions are tailored to meet strict scientific and regulatory standards from research to clinical development phases. Headquartered in Europe, and with locations in the United States, and Asia Polyplus supplies an extensive and growing, range of transfection reagents worldwide. Learn more at www.polyplus-transfection.com.